Bankroll – Clifton Park Arena http://www.cliftonparkarena.com/ Wed, 28 Apr 2021 12:40:20 +0000 en-US hourly 1 https://wordpress.org/?v=5.8 https://www.cliftonparkarena.com/wp-content/uploads/2021/04/cropped-icon-32x32.png Bankroll – Clifton Park Arena http://www.cliftonparkarena.com/ 32 32 Companies issue new bonds to pay off short-term debt amid pandemic https://www.cliftonparkarena.com/companies-issue-new-bonds-to-pay-off-short-term-debt-amid-pandemic/ Thu, 11 Mar 2021 05:33:49 +0000 https://www.cliftonparkarena.com/companies-issue-new-bonds-to-pay-off-short-term-debt-amid-pandemic/ Many companies used their lines of credit at the start of the pandemic to consolidate liquidity and prepare for a possible market collapse.

Now, a few months later, they are repaying the billions of those emergency funds they borrowed, as sweeping Federal Reserve interventions have opened up cheap access to financial markets and offered businesses a chance to strengthen their financial flexibility.

Companies raised more than $ 900 billion in capital through the sale of U.S. bonds between April 1 and August 31, more than double the volume from the previous year, according to data provider Dealogic. Dozens of them have used all or part of the proceeds from their bond sales to repay their revolving credit facilities, rating firm Moody’s Investors Service found.

Revolving credit facilities or lines of credit allow businesses to borrow up to a certain amount at a fixed interest rate to cover short-term financing needs. They are part of a larger funding tool set, which also includes bonds, short term loans, commercial paper, and asset-backed securities, which CFOs use.

“The amount of drawdown this year has been amazing,” said Enam Hoque, a senior engagement officer at Moody’s. Since the early days of the pandemic in the United States in March, companies have borrowed more than $ 310 billion through revolving credit facilities as of August 1, Hoque said. Most of this happened in March and April.

Howard hughes Corp.

, a Dallas-based real estate developer, borrowed $ 161 million on its existing lines of credit on March 10, CFO David O’Reilly said. “When the pandemic hit, we immediately took the facility away to have that money on the balance sheet,” Mr. O’Reilly said. “The importance of cash is at an all time high.”

Howard Hughes raised $ 750 million in early August to repay his outstanding financial obligations, including his revolving credit facility, which allows the company to use it again if needed. “Having access to these facilities gives you the ability to weather a financial storm,” Mr. O’Reilly said.

Companies must meet certain financial criteria once they remove their gun, a procedure called alliance or maintenance testing, which can occur as often as once a quarter.

“Companies don’t want to be put through the maintenance covenant test,” said Evan Friedman, head of covenant research at Moody’s. Going into the bond market can give companies more freedom, as they do not have to demonstrate financial readiness again until the debt matures.

But bond markets can shut down during times of financial stress, which is why many companies leaned on their guns in March and April.

Howard Hughes performed two quarterly tests of his compliance with loan agreements, both 45 days after the quarter close in March and June, according to Mr. O’Reilly. “Restrictive covenants are always a consideration,” he said, adding that the company remains in compliance.

Howard Hughes Chief Financial Officer David O’Reilly

 

Photo:

Howard Hughes Corp.

Another factor that helps companies is the high demand for corporate debt from investors.

Wyndham Hotels & Resorts Inc.,

the Parsippany, New Jersey-based hotel operator raised $ 500 million in bonds in August and used part of the funds to repay its existing credit facility, CFO Michele Allen said. “The new offering has been a huge success from our perspective,” Ms. Allen said. The bond has been oversubscribed almost six times, she said.

Low interest rates and other supportive measures from the Fed have lowered the interest companies have to offer investors.

Iron mountain Inc.,

an information storage and management company, this summer sold a total of $ 3.5 billion in bonds. This included a $ 1.1 billion bond issue in August, which, at 4.5%, was the lowest rate at which the company issued debt in the U.S. market, Barry Hytinen said, chief financial officer of the company.

Iron Mountain has paid off the upcoming bond debt along with a large chunk of his gun, Hytinen said. The new bonds extended the maturity of the company’s debt to an average of about 7.5 years, down from 5.5 years, Hytinen said.

MAC

Businesses can borrow on their revolving credit facilities as long as there is no material adverse change, or MAC, in their underlying financial conditions. Deteriorating quarterly results may indicate such a shift, which is why many companies rushed to withdraw their lines of credit in March before their next earnings report.

But for many businesses, gaining that extra flexibility comes at a price, as bond issues can be more expensive than what they charge for a line of credit.

The Brink’s Co.

, the security service provider known for its armored trucks, recently sold $ 400 million in new bonds and used a portion of the proceeds to pay off its revolving credit facility.

Brink’s has agreed to pay investors 5.5% interest, double the rate it pays for its billion-dollar gun, CFO Ron Domanico said. “To have the gun fully available, we felt it was a cheap insurance policy,” Domanico said. Brink’s used part of its revolving credit facility for an acquisition.

Credit scoring experts fear, however, that the availability of cheap debt will prevent companies from restructuring their operations. Existing creditors also have no say in whether or not companies should issue new debt, Friedman said. “Getting up in the face of distress is a concern for some businesses,” he said.

Write to Nina Trentmann at Nina.Trentmann@wsj.com

Copyright © 2020 Dow Jones & Company, Inc. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8

Source link

]]>
Income Fund announces regular monthly distribution https://www.cliftonparkarena.com/income-fund-announces-regular-monthly-distribution/ Thu, 11 Mar 2021 05:33:49 +0000 https://www.cliftonparkarena.com/income-fund-announces-regular-monthly-distribution/

DALLAS, March 2, 2021 – Highland Income Fund (NYSE: HFRO) (“ HFRO ” or the “ Fund ”) today announced its regular monthly distribution on its common shares of $ 0.0770 per share. The distribution will be payable on March 31, 2021 to shareholders of record at the close of business on March 24, 2021.

The Fund is a closed-end fund managed by Highland Capital Management Fund Advisors, LP (the “Manager”). The Fund will pursue its investment objective by investing primarily in the following categories of securities and instruments: (i) variable rate loans and other securities deemed to be variable rate investments; (ii) investments in securities or other instruments guaranteed directly or indirectly by real estate (including real estate investment trusts (“REITs”), preferred stocks, securities convertible into equity securities and mezzanine debt ); and (iii) other instruments, including, but not limited to, secured and unsecured fixed rate loans and corporate bonds, distressed securities, mezzanine securities, structured products (including , but not limited to mortgage-backed securities, secured loan bonds and asset-backed securities), convertible and preferred securities, equities (public and private), futures and options. The Fund’s investment objective is to provide a high level of current income consistent with preservation of capital in a registered fund format. The Fund declares and pays distributions of investment income on a monthly basis.

About the Highland Income Fund (HFRO)

The Highland Income Fund (“ HFRO ”) (NYSE:HFRO) is a closed-end fund managed by Highland Capital Management Fund Advisors, LP, an advisor on the Highland Capital Management alternative investment platform. Launched in 2000, HFRO aims to provide a high level of current income, compatible with the preservation of capital. For more information visit www.highlandfunds.com/income-fund.

About Highland Capital Management Fund Advisors, LP (HCMFA)

Highland Capital Management Fund Advisors, LP (“HCMFA”) is an investment advisor on Highland Capital Management (“Highland”) multi-billion dollar global alternative investment platform. HCMFA advises a range of registered funds, including open-end mutual funds, closed-end funds and an exchange-traded fund (“ETF”). Covering a range of asset classes and strategies, the funds leverage Highland’s investment capabilities, which include high yield credit, government stocks, real estate, private equity and special situations. , structured credit and vertical sectors specific to a sector and a region.

Investors should carefully consider the investment objectives, risks, fees and expenses of the Highland Income Fund before investing. This and other information can be found in the Fund’s prospectus, which you can obtain by calling 1-800-357-9167 or by visiting www.highlandfunds.com. Please read the prospectus carefully before investing.

On May 20, 2019, the Fund changed its name to Highland Income Fund and broadened its investment strategy by removing the Fund’s policy of, under normal market circumstances, investing at least 80% of its net assets in loans variable rate instruments and other securities deemed to be variable rate instruments. See the press release of March 20, 2019 for more details on the Fund’s name change and the broader investment strategy: ‘Highland Floating Rate Opportunities Fund announces name change to Highland Income Fund

As of the close of business on November 3, 2017, the Highland Floating Rate Fund changed from an open fund to a closed fund and began trading on the New York Stock Exchange under the symbol HFRO on November 6, 2017. The The performance data presented above for the periods prior to November 3, 2017 reflects that of the Class Z shares of the Fund when it was a variable capital fund, HFRZX. The closed-end fund pursues the same objective and the same investment strategy as before its conversion. The expense ratio is that of the Class Z shares of the Fund prior to its conversion.

The distribution may include a return of capital. Please see Distribution Source Notice 19 (a) -1 on the Highland Funds website for notices in Section 19 which provide estimates of the amounts and sources of the Fund’s distributions, which should not be used for tax reporting purposes.

There can be no assurance that the Fund will achieve its investment objectives.

The shares of closed-end investment companies frequently trade at a discount to the net asset value. The price of shares in the Fund is determined by a number of factors, many of which are beyond the control of the Fund. Therefore, the Fund cannot predict whether its shares will trade at, below or above net asset value. Past performance is no guarantee of future results.

Risk associated with closed funds. The Fund is a closed-end investment company designed primarily for long-term investors and not as a trading vehicle. No assurance can be given that a shareholder will be able to sell their shares on the New York Stock Exchange when they choose to do so, and no assurance can be given as to the price at which such a sale may be made.

Credit risk. The Sub-Fund may invest all or substantially all of its assets in senior loans or other securities rated below investment grade and unrated senior loans deemed by Highland to be of comparable quality. Securities rated below the investment grade are commonly referred to as “high yield securities” or “rotten securities”. They are considered primarily speculative with respect to the continued ability of the issuing company to repay principal and interest. Failure to pay expected interest and / or principal would result in a reduction in the income of the Fund, a reduction in the value of the Senior Loan in the event of non-payment and a potential decrease in the net asset value of the Fund. Investments in senior high yield loans and other securities may cause the net asset value to fluctuate more than if the Fund did not make such investments.

Senior Loan Risk. The London Interbank Offered Rate (“LIBOR”) is the average rate offered for various maturities of short-term loans between the major international banks that are members of the British Bankers Association. LIBOR is the benchmark interest rate index most commonly used to adjust variable rate loans. It is used in all global banking and financial industries to determine the interest rates of various financial instruments (such as debt instruments and derivatives) and loan agreements. Due to allegations of manipulation in 2012 and reduced activity in financial markets it measures, in July 2017, the Financial Conduct Authority (the “ FCA ”), the UK’s financial regulator Uni, has announced its desire to phase out the use of LIBOR by the end of 2021. Although the period from FCA’s announcement to the end of 2021 is generally long enough to allow market participants to pass When using another benchmark for new securities and transactions, uncertainty remains as to the future use of LIBOR and the specific replacement rate (s). Therefore, the potential effect of a transition from LIBOR on the Trust or the financial instruments used by the Trust cannot yet be determined. The transition process may involve, among other things, increased volatility or illiquidity in the markets for instruments that currently depend on LIBOR. The transition may also result in a change (i) in the value of certain instruments held by the Trust, (ii) in the cost of temporary borrowing to the Trust, or (iii) in the efficiency of operations related to the Trust such as blankets, as applicable. . When LIBOR is interrupted, the replacement rate for LIBOR may be lower than market expectations, which could negatively impact the value of preferred securities and variable rate or fixed to variable rate coupon debt securities. Such effects of the LIBOR transition, as well as other unanticipated effects, could result in losses to the Trust. Since the usefulness of LIBOR as a benchmark may deteriorate during the transition period, these effects may occur before the end of 2021.

Risk related to the real estate sector: Issuers primarily active in the real estate industry, including real estate investment trusts, may be exposed to risks similar to the risks associated with direct ownership of real estate, including: (i) changes in the terms and conditions of the economy and market; (ii) changes in the value of real estate; (iii) risks associated with local economic conditions, excessive construction and increased competition; (iv) increase in property taxes and operating costs; (v) changes in zoning laws; (vi) accident and conviction losses; (vii) variations in rental income, neighborhood values ​​or the attractiveness of the property to tenants; (viii) the availability of financing and (ix) the evolution of interest rates and financial leverage.

Risk of illiquidity of investments. Investments made by the Fund may be illiquid and therefore the Fund may not be able to sell such investments at prices which reflect the Investment Adviser’s assessment of their value or the amount initially paid for such investments. by the Fund.

Risk of continuous monitoring. On behalf of more than one lender, the agent will generally be responsible for administering and managing senior loans and, with respect to senior secured loans, servicing or monitoring the collateral.The financial difficulties of agents may present a risk to the Fund.

Source link

]]>
EVELO BIOSCIENCES: Discussion and analysis by management of the financial situation and operating results (form 10-K) https://www.cliftonparkarena.com/evelo-biosciences-discussion-and-analysis-by-management-of-the-financial-situation-and-operating-results-form-10-k/ Thu, 11 Mar 2021 05:33:49 +0000 https://www.cliftonparkarena.com/evelo-biosciences-discussion-and-analysis-by-management-of-the-financial-situation-and-operating-results-form-10-k/

The following discussion and analysis should be read in conjunction with our
consolidated financial statements and related notes included elsewhere in this
Annual Report on Form 10-K. This discussion and analysis and other parts of this
Annual Report on Form 10-K contain forward-looking statements based upon current
beliefs, plans and expectations that involve risks, uncertainties and
assumptions, such as statements regarding our plans, objectives, expectations,
intentions and projections. Our actual results and the timing of selected events
could differ materially from those anticipated in these forward-looking
statements as a result of several important factors, including without
limitation those set forth under "Summary Risk Factors" and Part I, Item1A "Risk
Factors" and elsewhere in this Annual Report on Form 10-K. You should carefully
read the "Risk Factors" section of this Annual Report on Form 10-K to gain an
understanding of the important factors that could cause actual results to differ
materially from our forward-looking statements. Please also see the section
entitled "Special Note Regarding Forward-Looking Statements." A discussion of
the year ended December 31, 2019 compared to the year ended December 31, 2018,
as well as a discussion of our 2018 fiscal year, specifically, has been reported
previously in our Annual Report on Form 10-K for the year ended December 31,
2019, filed with the SEC on February 14, 2020, under the heading "Management's
Discussion and Analysis of Financial Condition and Results of Operations."

Overview

We are discovering and developing a new class of oral biologics that are
intended to act on cells in the small intestine to produce therapeutic effects
throughout the body. The target cells in the small intestine play a central role
in governing human immune, metabolic and neurological systems. We refer to this
biology as the small intestinal axis, or SINTAXTM. We have built a platform to
discover and develop novel oral medicines which target the small intestinal
axis. By harnessing the small intestinal axis, we have the potential to
transform healthcare via medicines that have the potential to be effective,
safe, convenient and affordable and to thereby treat patients at all stages of
diseases and to treat patients globally.
Our first product candidates are orally delivered pharmaceutical preparations of
naturally occurring, specific single strains of microbes. In preclinical models,
our product candidates engaged immune cells in the small intestine and drove
changes in systemic biology without any observed systemic exposure. We have
observed in early clinical trials and preclinical studies that our approach led
to modulated immune responses throughout the body by acting on the small
intestinal axis. Our most advanced product candidate, EDP1815 is being developed
for the treatment of inflammatory diseases and the hyperinflammatory response
associated with COVID-19. Additional product candidates include EDP1867 and
EDP2939 for the treatment of inflammatory disease and EDP1908 for the treatment
of cancer.

Impact of COVID-19

At March 11, 2020, WHO has declared the COVID-19 outbreak a pandemic. The outbreak has led governments around the world to implement stringent measures to help control the spread of the virus, including quarantines, “safe-in-place” and “stay-at-home” orders. travel, business closures and reductions, and school closings.


The COVID-19 pandemic has had, and for an extended period of time is expected to
have, negative impacts on our operations and supply chain. Our ability to
continue to operate without any significant negative impacts will, in part,
depend on our ability to protect our employees and our supply chain. We have
endeavored to follow recommended actions of government and health authorities to
protect our employees with particular measures in place for those working in our
laboratories, such as staggered work shifts and flexible schedules, and
telecommuting for office workers. We are working with our CMOs to minimize
delays and disruptions to scheduled manufacturing batch runs for our product
candidates and to ensure conformity to product specifications.

The COVID-19 pandemic has impacted and continues to impact our enrollment of new
patients into, and the retention of existing patients in, our ongoing clinical
trials, due primarily to lower patient participation. The pandemic likely will
impact enrollment and retention of patients in new and existing clinical trials.
We continue to recruit individuals in line with the local and national
guidelines of the clinical research sites. We are keeping in close contact with
our CROs and clinical sites to provide support and guidance to ensure the safety
of the patients in our clinical trials. We have prioritized our drug supply
operations to secure the re-supply of patients currently enrolled in our
clinical trials.


                                       75

————————————————– ——————————

Contents


The extent to which the COVID-19 pandemic impacts our business and finances will
depend on future developments, which are highly uncertain and cannot be
predicted with confidence, such as the duration of the pandemic, travel
restrictions and social distancing in the United States, the United Kingdom and
other countries, business closures or business disruptions and the effectiveness
of actions taken in the United States, the United Kingdom and other countries to
contain and treat the disease. See "Risk Factors - The COVID-19 pandemic has
adversely impacted and may continue to adversely impact our business, including
our preclinical studies and clinical trials and finances." in Part I, Item 1A of
this Annually Report on Form 10-K.

Clinical programs


We are advancing SINTAX medicines to potentially treat a spectrum of immune
mediated diseases with an initial focus on inflammatory diseases and oncology.
The efficiency of our platform has, in a relatively short period of time,
allowed us to advance multiple product candidates into clinical trials for a
range of diseases.

EDP1815, a whole microbe candidate for inflammatory diseases

EDP1815 is in clinical development for psoriasis, atopic dermatitis and COVID-19.

Psoriasis


Based on previously reported positive clinical data in two cohorts of
individuals with mild and moderate psoriasis in a Phase 1b clinical trial, we
have advanced EDP1815 into a Phase 2 dose ranging trial, evaluating three doses
of A' EDP1815 in capsules versus placebo in approximately 225 individuals with
mild and moderate psoriasis. The primary endpoint of the trial is the mean
reduction in PASI score at 16 weeks. Other clinical measures of psoriasis are
also being evaluated. We initiated the Phase 2 clinical trial in October 2020
and have completed enrollment and, therefore, now plan to report topline data in
the third quarter of 2021. Clinical data from this trial, if positive, may
enable us to advance directly into Phase 3 registrational trials, subject to end
of Phase 2 discussions with regulatory agencies.

We intend to evaluate EDP1815 in additional inflammatory disease indications,
depending on the results from the Phase 2 trial. Potential indications include
psoriatic arthritis, axial spondylarthritis and rheumatoid arthritis.

Atopic dermatitis


In November 2018, we initiated our ongoing Phase 1b double-blind
placebo-controlled dose-escalating safety and tolerability trial of EDP1815 in
healthy volunteers and individuals with mild and moderate psoriasis or atopic
dermatitis. The primary endpoint of the phase 1b trial is safety and
tolerability.

In December 2020 and January 2021, we reported positive clinical data from a
cohort of patients with mild and moderate atopic dermatitis (n=24), randomized
2:1 to receive EDP1815 in capsules or placebo for 56 days. Atopic dermatitis is
the most common type of eczema. EDP1815 was well-tolerated with no
treatment-related adverse events of moderate or severe intensity, and no serious
adverse events. Secondary endpoints included a range of established markers of
clinical efficacy in atopic dermatitis, such EASI, IGA* BSA, and SCORAD scores.

The data showed consistent improvements in percentage change from baseline
compared to placebo for all three clinical scores: EASI, IGA*BSA, and SCORAD. In
addition, 7 out of 16 (44%) patients treated with EDP1815 achieved an outcome of
a 50% improvement from baseline in EASI score by day 70, compared with 0% in the
placebo group, showing sustained improvement in those patients responding to
EDP1815.

In addition to physician-reported clinical outcomes, this trial also assessed
patient-reported outcomes. Treatment with EDP1815 resulted in clinically
meaningful improvement in the DLQI and POEM. These patient-reported outcomes
capture the important impact of the disease on patients, including the domains
of itch and sleep, both of which saw improvements in patients receiving EDP1815
in the trial. All five measures of itch within the Pruritus-NRS, SCORAD, POEM,
and DLQI showed greater improvements in the treated group at day 56 compared
with placebo. These results provide further evidence that modulating SINTAX can
drive significant clinical benefit without the need for systemic exposure.


                                       76

————————————————– ——————————

Contents

Subject to regulatory approval, we expect to launch a Phase 2 trial of EDP1815 in atopic dermatitis in the third quarter of 2021.

COVID-19[feminine


EDP1815 is being evaluated in two ongoing clinical trials for the treatment of
hospitalized COVID-19 patients. The first is a Phase 2 double-blind,
placebo-controlled clinical trial evaluating the safety and efficacy of EDP1815
for the treatment of individuals diagnosed with COVID-19 early in the course of
their disease. The clinical trial initially will evaluate 60 individuals to
determine if early intervention with EDP1815 can prevent the progression of
COVID-19 symptoms and the development of COVID-Related complications.
Individuals who have presented at the emergency room within the last 36 hours
and tested positive for SARS-CoV-2 are randomized 1:1 to receive the capsule
formulation of EDP1815 targeted for release in the small intestine or placebo
for 14 days, along with the standard of care. The primary endpoint is reduced
requirements for oxygen therapy, as measured by the ratio of oxygen saturation
(SpO2) / fraction of inspired oxygen (FiO2). Key secondary endpoints include
total symptom duration, progression along the WHO scale of disease severity, and
mortality. The trial is led by Reynold A. Panettieri, Jr., M.D., Vice Chancellor
for Translational Medicine and Science at Rutgers Biomedical and Health Sciences
and Professor of Medicine at Rutgers Robert Wood Johnson Medical School.

EDP1815 is also included as a treatment arm in the TACTIC-E clinical trial.
TACTIC-E is a Phase 2/3 randomized trial, sponsored by Cambridge University
Hospitals NHS Foundation Trust, that is expected to evaluate up to 469 patients
per arm at Addenbrooke's Hospital and other leading clinical centers in the
United Kingdom and select international sites. The trial is investigating the
safety and efficacy of certain experimental therapies in the prevention and
treatment of life-threatening complications associated with COVID-19 in
hospitalized individuals at early stages of the disease. The trial is enrolling
individuals with COVID-19 who have identified risk factors for developing severe
complications and are at risk of progression to the intensive care unit or
death. The primary outcome measure of the trial is time to incidence (up to day
14) of any one of the following: death, mechanical ventilation, extracorporeal
membrane oxygenation, cardiovascular organ support, renal failure,
hemofiltration or dialysis. Secondary outcome measures include duration of stay
in hospital, duration of oxygen therapy, changes in biomarkers associated with
COVID-19 progression, and time to clinical improvement.

As a result of the varying infection rates and resulting hospitalizations that
have occurred with the pandemic, we experienced slower than expected enrollment
early on in both trials and now expect to report data from the clinical trial
conducted at the Robert Wood Johnson University Hospital and interim safety data
and futility analysis from TACTIC-E in the second quarter of 2021. In order to
expedite patient recruitment and expand access to potential therapies for
COVID-19, new trial sites have been opened for TACTIC-E, including in the United
Kingdom and Mexico.

Modèle expérimental humain de l’inflammation


In addition to testing our product candidates in patients with inflammatory
disease, we also have employed a human experimental model of inflammation in
healthy volunteers. This model is very similar in design to a standard
preclinical model of T cell driven inflammation. We have recently used this
model to test two different concentrations of EDP1815 to investigate the
relative effectiveness of the different concentrations. A total of 32 volunteers
were enrolled into the trial and treated with either EDP1815 (n=12 per
formulation) or placebo (n=4 per formulation) daily for 28 days. The
participants were immunized with an antigen used in preclinical inflammation
experiments. After 28 days of daily oral dosing with EDP1815 or placebo, the
participants were given a skin challenge with the same antigen, which causes
measurable skin inflammation a day later. Inflammation was determined by
measuring five parameters in the skin at the challenge site.

The increased concentration of drug results from improvements made in the
commercial-scale manufacturing process, referred to as A2. This is the same
active drug at four times the concentration compared to a prior manufacturing
process, referred to as A'. Twelve participants were dosed with A' EDP1815.
Another 12 participants were given the higher concentration A2 EDP185. Eight
participants who received a placebo were divided between the two treatment
groups. The results are in the figure below.



                                       77
--------------------------------------------------------------------------------
  Table of Contents
A2 EDP1815 is more effective than A' at same total dose in human experimental
model of inflammation
                    [[Image Removed: evlo-20201231_g4.jpg]]The higher concentration A2, given in fewer capsules, resulted in numerically superior reductions across the full range of skin scores compared to A 'and placebo.  A2 and A 'were given at the same total daily dose of drug.  These results are consistent with preclinical data that showed increased drug concentration resulted in increased activity.  This is a key advance in our understanding of how to get more benefit from SINTAX medicine candidates.  We plan to evaluate tablets and capsules containing the higher concentration A2 EDP1815 in patients with psoriasis in our on-going Phase 1b trial, and expect to report data in the third quarter of 2021. Results from the Phase 1b trial and our on-going Phase 2 trial in psoriasis will position us to go forward into Phase 3 trials with an optimized dose and formulation of EDP1815, which may further improve on the positive results already seen.

EDP1867 – a whole microbe candidate for inflammatory diseases


EDP1867 is an inactivated investigational oral biologic being developed for the
treatment of inflammatory diseases. EDP1867 was selected from a broad screen of
single strains of microbes in in vitro cellular assays and in vivo models of
inflammation. In preclinical studies EDP1867 was shown to resolve multiple
pathways of inflammation. This observed activity suggests a number of possible
initial clinical indications for EDP1867, including TH2-dependent inflammation
which underlies atopic diseases and a large spectrum of asthma. We initiated our
first Phase 1b clinical trial of EDP1867 in healthy volunteers and patients with
moderate atopic dermatitis in February of 2021 and expect to report interim data
in the fourth quarter of 2021.

EDP2939 – an extracellular vesicle (EV) candidate for inflammatory diseases


EDP2939 is an EV investigational oral biologic being developed for the treatment
of inflammatory diseases. EDP2939 is the first EV product candidate we have
nominated in our inflammation program and we anticipate initiation of clinical
development in 2022.

EDP1908 – an EV candidate for oncology


In December 2020, we announced EDP1908 as our lead candidate in oncology
following presentation of preclinical data at the Society for Immunotherapy for
Cancer meeting in November 2020. Preclinical data presented showed that orally
administered EDP1908, an EV, resulted in superior tumor growth control versus
the parent microbial strain or anti-PD-1 therapy, with an observed
dose-dependent reduction in tumor growth. We anticipate initiation of clinical
development in 2022.

Funding

We were incorporated and commenced operations in 2014. Since our incorporation,
we have devoted substantially all of our resources to developing our clinical
and preclinical candidates, building our intellectual property portfolio and
process development and manufacturing function, business planning, raising
capital and providing general and administrative support for these operations.
To date, we have financed our operations


                                       78
--------------------------------------------------------------------------------
  Table of Contents
primarily with proceeds from sales of common and convertible preferred stock to
our equity investors and borrowings under loan and security agreements with
financial institutions.
Through December 31, 2020, we have received gross proceeds of $332.0 million
through the issuance of our common stock, convertible preferred stock and
borrowings under our loan and security agreements.
On July 19, 2019 we entered into a loan and security agreement, as amended, with
K2HV providing for up to $45.0 million in potential debt financing, the proceeds
of which were used to prepay our entire existing outstanding loan balance, and
additional amounts are intended for the advancement of our research and
development activities related to our pipeline of oral biologics and for general
corporate purposes. Under terms of the 2019 Credit Facility, the aggregate
principal amount of $45.0 million was available in three tranches of term loans
of $20.0 million, $10.0 million, and $15.0 million, respectively. At closing on
July 19, 2019, we borrowed $20.0 million, representing the first tranche under
the 2019 Credit Facility. On July 14, 2020, we drew down the second tranche of
$10.0 million and availability of the third tranche expired on January 15, 2021.
Interest on the outstanding loan balance accrues at a variable rate equal to the
greater of (i) 8.65% and (ii) the prime rate as published in the Wall Street
Journal, plus 3.15%. We are required to make monthly interest-only payments
through February 2022. Subsequent to the interest-only period, we are required
to make equal monthly principal payments plus any accrued interest until the
loans mature in August 2024. Upon final payment or prepayment of the loans, we
are required to pay a final payment equal to 4.3% of the loans borrowed.
In June 2020, we sold 13,800,000 shares of our common stock in an underwritten
public offering at a public offering price of $3.75 per share, for gross
proceeds of $51.8 million and net proceeds of $48.4 million, after deducting
underwriting discounts and commission and other offering expenses payable by us.
For the year ended December 31, 2020, pursuant to the June 2019 sales agreement
with Cowen and Company, LLC, we sold 1,232,131 shares of our common stock, in
"at-the-market" offerings under a registration statement on Form S-3 that we
previously filed with the SEC with offering prices ranging between $4.25 to
$11.15 per share for gross proceeds of $6.8 million and net proceeds of
$6.6 million, after deducting commission and other offering expenses payable by
us. In January 2021, we issued 139,734 additional shares of our common stock
with offering prices ranging between of $12.54 and $13.17 per share for gross
proceeds of $1.8 million and net proceeds of $1.7 million, after deducting
commission and other offering expenses payable by us.

On February 2, 2021, we sold 5,175,000 shares of our common stock in an
underwritten public offering at a public offering price of $15.00 per share,
including the underwriters' exercise of their option to purchase 675,000 shares
to cover over-allotment, generating gross proceeds of $77.6 million and net
proceeds of $73.0 million, after deducting underwriting discounts and
commissions, exclusive of other offering expenses payable by us.
On January 28, 2021, we entered into a stock purchase agreement with ALJ Health
Care & Life Sciences Company Limited ("ALJ"), pursuant to which on February 2,
2021, ALJ purchased $7.5 million of our common stock in a private placement at a
purchase price of $15.00 per share. The sale of these 500,000 shares was not
registered under the Securities Act.
We are a development stage company and have not generated any revenue. All of
our product candidates are in early clinical or preclinical development. Our
ability to generate product revenue sufficient to achieve profitability will
depend heavily on the successful development and eventual commercialization of
one or more of our product candidates. Since our inception, we have incurred
significant operating losses and we continue to incur significant research and
development and other expenses related to our ongoing operations. For the years
ended December 31, 2020 and 2019 our net loss was $93.7 million and $85.5
million, respectively. As of December 31, 2020, we had an accumulated deficit of
$292.5 million. We do not expect to generate revenue from sales of any products
for the foreseeable future, if at all.
We expect that our expenses will increase substantially in connection with our
ongoing activities, particularly as we:
•continue the ongoing clinical trials for EDP1815 and EDP1867;
•initiate additional clinical trials for EDP1815;
•initiate or advance the clinical development of additional product candidates;
•conduct research and continue preclinical development of potential product
candidates;
•make strategic investments in manufacturing capabilities, including potentially
planning and building our own manufacturing facility;


                                       79
--------------------------------------------------------------------------------
  Table of Contents
•maintain our current intellectual property portfolio and opportunistically
acquire complementary intellectual property;
•increase research and development employees and employee-related expenses
including salaries, benefits, travel and stock-based compensation expense; and
•seek to obtain regulatory approvals for our product candidates.
In addition, if we obtain marketing approval for any of our product candidates,
we expect to incur significant commercialization expenses related to product
manufacturing, marketing, sales and distribution.
As a result, we will need additional financing to support our continuing
operations. Until such time as we can generate significant revenue from product
sales, if ever, we expect to finance our operations through a combination of
public or private equity or debt financings or other sources, which may include
collaborations with third parties. Adequate additional financing may not be
available to us on acceptable terms, or at all. Our inability to raise capital
as and when needed would have a negative impact on our financial condition and
our ability to pursue our business strategy. We will need to generate
significant revenue to achieve profitability, and we may never do so.
Because of the numerous risks and uncertainties associated with drug
development, we are unable to predict the timing or amount of increased expenses
or when or if we will be able to achieve or maintain profitability. Even if we
are able to generate revenue from product sales, we may not become profitable.
If we fail to become profitable or are unable to sustain profitability on a
continuing basis, then we may be unable to continue our operations at planned
levels and be forced to reduce or terminate our operations.
As of December 31, 2020, our principal source of liquidity is cash and cash
equivalents, which totaled approximately $68.9 million. During the first quarter
of 2021 we raised net proceeds of $82.2 million from the issuance of common
stock exclusive of certain other fees payable by us. We expect that our existing
cash and cash equivalents as of December 31, 2020, together with the net
proceeds raised in the first quarter of 2021 from the issuance of our common
stock, will enable us to fund our planned operating expenses and capital
expenditure requirements into the third quarter of 2022. We have based these
estimates on assumptions that may prove to be wrong, and we may use our
available capital resources sooner than we currently expect. See "Liquidity and
Capital Resources."

Financial Operations Overview
Revenue
We have not generated any revenue since our inception and do not expect to
generate any revenue from the sale of products in the near future if at all. If
our development efforts for our current product candidates or additional product
candidates that we may develop in the future are successful and result in
marketing approval or if we enter into collaboration or license agreements with
third parties, we may generate revenue in the future from a combination of
product sales or payments from such collaboration or license agreements.
Operating Expenses
Our operating expenses since inception have consisted primarily of research and
development activities and general and administrative costs.
Research and Development Expenses
Research and development expenses consist primarily of costs incurred for our
research activities, including our discovery efforts, and the development of our
product candidates, which include:
•expenses incurred under agreements with third parties, including investigative
sites, external laboratories and CROs, that conduct research, preclinical
activities and clinical trials on our behalf
•manufacturing process-development costs as well as technology transfer and
other expenses incurred with contract manufacturing organizations, or CMOs, that
manufacture drug substance and drug product for use in our preclinical
activities and any current or future clinical trials;
•salaries, benefits and other related costs, including stock-based compensation
expense, for personnel in our research and development functions;
•expenses to acquire technologies to be used in research and development;
•costs of outside consultants, including their fees, stock-based compensation
and related travel expenses;


                                       80
--------------------------------------------------------------------------------
  Table of Contents
•the cost of laboratory supplies and acquiring, developing and manufacturing
preclinical and clinical trial materials;
•costs related to compliance with regulatory requirements; and
•facility-related expenses, which include direct depreciation costs and
allocated expenses for rent and maintenance of facilities and other operating
costs.
We expense research and development costs as incurred. We recognize external
development costs based on an evaluation of the progress to completion of
specific tasks using information provided to us by our vendors and our clinical
investigative sites. Payments for these activities are based on the terms of the
individual agreements, which may differ from the pattern of costs incurred, and
are reflected in our consolidated financial statements as prepaid or accrued
research and development expenses. Nonrefundable advance payments for goods or
services to be received in the future for use in research and development
activities are deferred and capitalized, even when there is no alternative
future use for the research and development. The capitalized amounts are
expensed as the related goods are delivered or the services are performed.
Our primary focus of research and development since inception has been building
a platform to enable us to develop medicines based on an understanding of the
gut-body network and to show potential clinical utility and develop the first
set of clinical assets. Our platform and program expenses consist principally of
costs, such as preclinical research, process development research, clinical and
preclinical manufacturing activity costs, clinical development costs, licensing
expense as well as an allocation of certain indirect costs, facility and office
related expenses. We do not allocate personnel costs, which include salaries,
discretionary bonus and stock-based compensation costs, as such costs are
separately classified as research and development personnel costs.
Research and development activities are central to our business model. Product
candidates in later stages of clinical development generally have higher
development costs than those in earlier stages of clinical development,
primarily due to the increased size and duration of later-stage clinical trials.
We expect that our research and development expenses will continue to increase
in the foreseeable future as we continue our ongoing clinical trials for our
product candidates, including EDP1815 and EDP1867, initiate additional clinical
trials of other product candidates, including EDP2939 and EDP1908, continue to
discover and develop additional product candidates, hire additional research and
development personnel, build manufacturing capabilities and expand into
additional therapeutic areas.
At this time, we cannot reasonably estimate or know the nature, timing and
estimated costs of the efforts that will be necessary to complete the
development of, and obtain regulatory approval for, any of our product
candidates. We are also unable to predict when, if ever, material net cash
inflows will commence from sales or licensing of our product candidates. This is
due to the numerous risks and uncertainties associated with drug development,
including the uncertainty of:
•our ability to add and retain key research and development personnel;
•our ability to successfully develop, obtain regulatory approval for, and then
successfully commercialize, our product candidates;
•our successful enrollment in and completion of clinical trials;
•the costs associated with the development of our current product candidates
and/or any additional product candidates we identify in-house or acquire through
collaborations;
•our ability to discover, develop and utilize biomarkers to demonstrate target
engagement, pathway engagement and the impact on disease progression of our
product candidates;
•our ability to establish an appropriate safety profile with IND-enabling
toxicology studies;
•our ability to establish and maintain agreements with CMOs and other entities
for clinical trial supply and future commercial supply, if our product
candidates are approved;
•the terms and timing of any collaboration, license or other arrangement,
including the terms and timing of any milestone payments thereunder;
•our ability to obtain and maintain patent, trade secret and other intellectual
property protection and regulatory exclusivity for our product candidates if and
when approved;
•our receipt of marketing approvals from applicable regulatory authorities;


                                       81
--------------------------------------------------------------------------------
  Table of Contents
•our ability to commercialize products, if and when approved, whether alone or
in collaboration with others; and
•the continued acceptable safety profiles of the product candidates following
approval.
A change in any of these variables with respect to the development of any of our
product candidates would significantly change the costs, timing and viability
associated with the development of that product candidate. We expect our
research and development expenses to increase at least over the next several
years as we continue to implement our business strategy, advance our current
programs, expand our research and development efforts, seek regulatory approvals
for any product candidates that successfully complete clinical trials, identify
and develop additional product candidates and incur expenses associated with
hiring additional personnel to support our research and development efforts.
General and Administrative Expenses
General and administrative expenses consist primarily of salaries and other
related costs, including stock-based compensation, for personnel in our
executive, finance, corporate and business development, and administrative
functions. General and administrative expenses also include legal fees relating
to patent and corporate matters; professional fees for accounting, auditing, tax
and administrative consulting services; insurance costs; administrative travel
expenses; and facility-related expenses, which include direct depreciation costs
and allocated expenses for rent and maintenance of facilities and other
operating costs.
We anticipate that our general and administrative expenses will increase in the
future as we increase our headcount to support the expected growth in our
research and development activities and the potential commercialization of our
product candidates. We also expect to incur increased expenses associated with
being a public company, including increased costs of accounting, audit, legal,
regulatory and tax-related services associated with maintaining compliance with
exchange listing and SEC requirements, director and officer insurance costs and
investor and public relations costs.
Interest (Expense) Income, Net
Interest income (expense), net consisted primarily of interest earned on our
cash, cash equivalents and short-term investments balances offset by interest
expense at the stated rate on borrowings under our loan and security agreement,
amortization of deferred financing costs and interest expense related to the
accretion of debt discount associated with the loan and security agreement.
Other (Expense) Income, Net
For the year ended December 31, 2020, other income (expense), net primarily
consists of foreign currency gains and government grants related to our
operations in the United Kingdom.
Income Taxes
Income tax expense primarily relates to tax expense at our UK subsidiary.
Since our inception in 2014, we have not recorded any U.S. federal or state
income tax benefits for the net losses we have incurred in each year or our
earned research and development tax credits, due to our uncertainty of realizing
a benefit from those items.


                                       82
--------------------------------------------------------------------------------
  Table of Contents
Results of Operations
Comparison of Years Ended December 31, 2020 and 2019
The following table summarizes our results of operations for the years ended
December 31, 2020 and 2019 (in thousands):
                                       Year Ended December 31,            Increase/
                                         2020               2019         (Decrease)
Operating expenses:
Research and development         $      69,616           $  63,128      $     6,488
General and administrative              22,270              23,229             (959)
Total operating expenses                91,886              86,357            5,529
Loss from operations                   (91,886)            (86,357)          (5,529)
Other (expense) income:
Interest (expense) income, net          (2,109)              1,049           (3,158)
Other income, net                          738                  26              712
Other (expense) income, net             (1,371)              1,075           (2,446)
Net loss before income taxes           (93,257)            (85,282)          (7,975)
Income tax expense                        (409)               (190)            (219)
Net loss                         $     (93,666)          $ (85,472)     $    (8,194)

Research and development costs (in thousands):

                                                                Year Ended December 31,                  Increase/
                                                                2020                    2019             (Decrease)
Platform expenses                                      $      11,487                $  10,468          $     1,019
Inflammation programs                                         30,467                   25,161                5,306
Oncology programs                                              5,487                    9,226               (3,739)

Research and development personnel costs (including stock-based compensation)

                                     22,175                   18,273                3,902
Total research and development expenses                $      69,616        

$ 63,128 $ 6,488



Research and development expenses were $69.6 million for the year ended
December 31, 2020, compared to $63.1 million for the year ended December 31,
2019. The increase of $6.5 million was primarily driven by a $5.3 million
increase in inflammation program costs due to the progression of EDP1815 to
Phase 2, the addition of COVID-19 studies utilizing EDP-1815, and costs incurred
in contract manufacturing to enable EDP1867 Phase 1 clinical trials partially
offset by the closeout of the EDP1066 program. In addition, personnel costs
increased by $3.9 million due to increases in clinical development and technical
operations headcount to support increased clinical program activities. Finally,
there was a $1.0 million increase for platform expenses which is in line with
our strategy to maximize the potential of our platform. These increases were
partially offset by a $3.7 million decrease in our oncology program costs,
primarily related to the clinical trial stage and the impact of the COVID-19
pandemic on patient recruitment. Overall, we expect that our research and
development expenses will continue to increase in the foreseeable future as we
continue our clinical trials for our product candidates, including EDP1815 and
EDP1867, initiate new clinical trials, potentially expand into additional
therapeutic areas, continue discovery and development efforts for additional
product candidates, hire additional research and development personnel, and seek
to increase manufacturing capabilities.
General and Administrative Expenses (in thousands):
                                                                 Year Ended December 31,                  Increase/
                                                                 2020                    2019             (Decrease)

General and administrative staff costs (including stock-based compensation)

                               $      12,261                $  12,345          $       (84)
Professional fees                                               5,513                    6,725               (1,212)
Facility costs, office expense and other                        4,496                    4,159                  337
Total general and administrative expenses               $      22,270                $  23,229          $      (959)




                                       83
--------------------------------------------------------------------------------
  Table of Contents
General and administrative expenses were $22.3 million for the year ended
December 31, 2020, compared to $23.2 million for the year ended December 31,
2019. The decrease of $1.0 million was primarily driven by $1.2 million lower
cost associated with legal, consulting and other professional fees, partially
offset by higher IT, facilities and other office expenses costs. We expect this
decrease to be temporary and general and administrative expenses to increase due
to higher personnel and related costs, professional, legal, and patent fees and
consulting expenses in support of our continued growth.
Other (Expense) Income, Net
Other income (expense), net for the year ended December 31, 2020 was expense of
$1.4 million compared to income of $1.1 million for the year ended December 31,
2019. This decrease was primarily driven by a decrease in interest income as a
result of lower interest rates and a lower cash and cash equivalent balance and
an increase in interest expense as a result of a higher interest rate on a
greater principal balance from the 2019 Credit Facility, partially offset by
foreign currency gains and a grant related to our operations in the United
Kingdom.
Net Loss

Net loss was $93.7 million for the year ended December 31, 2020, compared to
$85.5 million for the year ended December 31, 2019. The increase of $8.2 million
was primarily the result of the increase in research and development expenses
and decrease in other income (expense), net discussed above, partially offset by
the decrease in general and administrative expenses discussed above.

Liquidity and Capital Resources
To date, we have financed our operations primarily with the proceeds from
issuance of our common stock combined with proceeds from previous sales of our
convertible preferred stock to our equity investors and borrowings under loan
and security agreements. From our inception through December 31, 2020, we have
received gross proceeds of $332.0 million from such transactions, including
$30.0 million borrowed under the 2019 Credit Facility. As of December 31, 2020,
we had cash and cash equivalents of $68.9 million and an accumulated deficit of
$292.5 million. During the first quarter of 2021 we raised net proceeds of $82.2
million from the issuance of common stock exclusive of certain other fees
payable by us. We expect that our existing cash and cash equivalents as of
December 31, 2020, together with the net proceeds raised in the first quarter of
2021 from the issuance of our common stock, will enable us to fund our planned
operating expenses and capital expenditure requirements into the third quarter
of 2022.

On June 3, 2019, we filed a Registration Statement on Form S-3 (File No.
333-231911) (the "Shelf") with the SEC under which we can offer from time to
time common stock, preferred stock, debt securities, warrants and/or units of
any combination thereof in an aggregate amount of up to $200.0 million over a
period of up to three years from the date of its effectiveness on June 6, 2019.
We also simultaneously entered into a sales agreement with Cowen and Company,
LLC, as sales agent, providing for the offering, issuance and sale by us of up
to an aggregate $50.0 million of our common stock from time to time in
"at-the-market" offerings under the Shelf. For the year ended December 31, 2020,
we had issued 1,232,131 shares of our common stock with offering prices ranging
between $4.25 to $11.15 per share for gross proceeds of $6.8 million and net
proceeds of $6.6 million, after deducting commission and other offering expenses
payable by us. In January 2021, we issued 139,734 additional shares of our
common stock with offering prices ranging between $12.54 and $13.17 per share
for gross proceeds of $1.8 million and net proceeds of $1.7 million, after
deducting commission and other offering expenses payable by us.
On February 2, 2021, we sold 5,175,000 shares of our common stock in an
underwritten public offering at a public offering price of $15.00 per share,
including the underwriters' exercise of their option to purchase 675,000 shares
to cover over-allotment, generating gross proceeds of $77.6 million and net
proceeds of underwriting discounts and commission of $73.0 million, exclusive of
certain other offering expenses payable by us.
On January 28, 2021, we entered into a stock purchase agreement with ALJ,
pursuant to which on February 2, 2021, ALJ purchased $7.5 million of our common
stock in a private placement at a purchase price of $15.00 per share. The sale
of such shares will not be registered under the Securities Act.
Debt financing
On July 19, 2019 we entered into the 2019 Credit Facility with K2HV providing
for up to $45.0 million of current and future potential debt financing. The
aggregate principal amount was available in three tranches of term loans of
$20.0 million, $10.0 million, and $15.0 million, respectively. At closing on
July 19, 2019, we borrowed $20.0 million,


                                       84
--------------------------------------------------------------------------------
  Table of Contents
representing the first tranche under the 2019 Credit Facility. On July 14, 2020,
we drew down the second tranche of $10.0 million and availability of the third
tranche expired on January 15, 2021.

Interest on the outstanding loan balance will accrue at a variable rate equal to
the greater of (i) 8.65% and (ii) the prime rate as published in the Wall Street
Journal, plus 3.15%. We are required to make monthly interest-only payments
through February 2022. Subsequent to the interest-only period, we are required
to make equal monthly principal payments plus any accrued interest until the
loans mature in August 2024. Upon final payment or prepayment of the loans, we
are required to pay a final payment equal to 4.3% of the loans borrowed. We have
an option to prepay the loans in whole, subject to a prepayment fee of 2% of the
amount prepaid or, if the prepayment occurs after the 18-month anniversary of
the funding date of the loans, 1% of the amount prepaid.
Contemporaneous with the closing of the first tranche of funding described
above, we repaid the entire $15.0 million loan balance outstanding under an
existing loan and security agreement with a separate financial institution. In
accordance with the agreement underlying the prior debt facility, we paid an
additional 0.5% prepayment fee as additional expense.
We have incurred losses and generated negative operating cash flows since our
inception and anticipate that we will continue to incur losses for at least the
next several years. We incurred net losses of approximately $93.7 million and
$85.5 million for the years ended December 31, 2020 and 2019, respectively.
Until such time, if ever, as we can generate revenue from product sales, we
expect to finance our cash needs through a combination of equity offerings, debt
financings and potential collaborations, license and development agreements. To
the extent that we raise additional capital through future equity offerings or
debt financings, the ownership interest of common stockholders will be diluted,
and the terms of these securities may include liquidation or other preferences
that adversely affect the rights of the common stockholders. Debt and equity
financings, if available, may involve agreements that include covenants limiting
or restricting our ability to take specific actions, such as incurring
additional debt, making capital expenditures or declaring dividends. There can
be no assurance that such financings will be obtained on terms acceptable to us,
if at all. If we are unable to raise additional capital in sufficient amounts or
on terms acceptable to us, we may have to significantly delay, scale back or
discontinue our research and development programs or future commercialization
efforts. If we raise additional funds through collaborations, strategic
alliances or marketing, distribution or licensing arrangements with third
parties for one or more of our current or future drug candidates, we may be
required to relinquish valuable rights to our technologies, future revenue
streams, research programs or drug candidates or to grant licenses on terms that
may not be favorable to us. Our failure to raise capital as and when needed
would have a material adverse effect on our financial condition and our ability
to pursue our business strategy.
Cash Flows
The following table summarizes our sources and uses of cash for each of the
periods presented (in thousands):
                                                                        

End of year the 31st of December,

                                                                        2020                   2019
Cash used in operating activities                               $     (73,063)             $  (71,980)
Cash (used in)/provided by investing activities                        (1,315)                 51,970
Cash provided by financing activities                                  65,465                   4,992

Net decrease in cash, cash equivalents and restricted cash ($ 8,913)

             $  (15,018)


Operating Activities
Net cash used in operating activities for the year ended December 31, 2020, was
$73.1 million, primarily due to our net loss of $93.7 million. This was
partially offset by non-cash charges, including stock-based compensation expense
of $8.5 million, depreciation expense of $2.0 million, lease expense of $2.0
million and reduction in working capital of $7.8 million.
Net cash used in operating activities for the year ended December 31, 2019,
was $72.0 million, primarily due to our net loss of $85.5 million. This was
partially offset by non-cash charges, including stock-based compensation expense
of $8.2 million, depreciation expense of $1.8 million, and reduction in working
capital of $3.5 million.
Investing Activities
Net cash used in investing activities for the year ended December 31, 2020, was
$1.3 million, primarily due to the purchase of capital equipment.


                                       85
--------------------------------------------------------------------------------
  Table of Contents
Net cash provided by investing activities for the year ended December 31, 2019,
was $52.0 million, primarily consisting of maturity of investments totaling
$55.0 million, slightly offset by the purchase of capital equipment totaling
$3.0 million during the year.
Financing Activities
Net cash provided by financing activities for the year ended December 31, 2020
was $65.5 million, primarily due to proceeds from issuance of commons stock
totaling $55.0 million, issuance of long-term debt under our 2019 Credit
Facility totaling $10.0 million and proceeds from the issuance of common stock
in connection with the exercise of options totaling $0.5 million.
Net cash provided by financing activities for the year ended December 31, 2019
was $5.0 million, primarily due to proceeds from the issuance of long-term debt
under our 2019 Credit Facility and proceeds from the issuance of common stock in
connection with the exercise of options totaling $0.5 million, partially offset
by the repayment of our prior debt facility.
Funding Requirements
We have incurred losses and cumulative negative cash flows from operations since
our inception. As of December 31, 2020, we had an accumulated deficit of $292.5
million. We anticipate that we will continue to incur significant losses for at
least the next several years. We expect that our research and development and
general and administrative expenses will continue to increase. As a result, we
will need additional capital to fund our operations, which we may raise through
a combination of the sale of equity, debt financings, or other sources,
including potential collaborations.
We expect our expenses to increase substantially in connection with our ongoing
development activities related to the initiation of clinical studies and
preclinical work on additional monoclonal microbial product candidates, which
are still in development, and our follow-on therapeutics and other programs. In
addition, we expect to incur additional costs associated with increased
personnel and operating as a public company. We anticipate that our expenses
will increase substantially if and as we:
•continue our proof of concept clinical trials of EDP1815;
•advance the clinical development of any additional monoclonal microbial product
candidates;
•conduct research and continue preclinical development of potential product
candidates;
•make strategic investments in manufacturing capabilities, including potentially
planning and building a small-scale commercial manufacturing facility;
•maintain our current intellectual property portfolio and opportunistically
acquire complementary intellectual property;
•seek to obtain regulatory approvals for our product candidates;
•potentially establish a sales, marketing and distribution infrastructure
and scale-up manufacturing capabilities to commercialize any products for which
we may obtain regulatory approval;
•add clinical, scientific, operational, financial and management information
systems and personnel, including personnel to support our product development
and potential future commercialization efforts and to support our transition to
a public company; and
•experience any delays or encounter any issues with any of the above, including
but not limited to failed studies, complex results, safety issues or other
regulatory challenges.
During the first quarter of 2021 we raised net proceeds of $82.2 million from
the issuance of common stock exclusive of certain other fees payable by us. We
expect that our cash and cash equivalents as of December 31, 2020 together with
the net proceeds raised in the first quarter of 2021 from the issuance of our
common stock, will enable us to fund our planned operating expenses and capital
expenditure requirements into the third quarter of 2022. Our forecast of the
period of time through which our financial resources will be adequate to support
our operations is a forward-looking statement and involves risks and
uncertainties, and actual results could vary as a result of a number of factors.
Our forecast is based on assumptions that may prove to be wrong, and we may use
our available capital resources sooner than we currently expect.

Because of the numerous risks and uncertainties associated with the development
of EDP1815 and EDP1867, any additional monoclonal microbial product candidates
or any follow-on programs and because the extent to which we may enter into
collaborations with third parties for development of these product candidates is
unknown, we are


                                       86
--------------------------------------------------------------------------------
  Table of Contents
unable to estimate the amounts of increased capital outlays and operating
expenses associated with completing the research and development of our product
candidates. Our future capital requirements for our technology platform or our
other programs will depend on many factors, including:
•the progress and results of clinical studies of EDP1815 and EDP1867;
•the cost of manufacturing clinical supplies of our product candidates;
•the scope, progress, results and costs of preclinical development, laboratory
testing for any other potential product candidates;
•the costs, timing and outcome of regulatory review of our product candidates;
•the costs and timing of future commercialization activities, including
manufacturing, marketing, sales and distribution, for any of our product
candidates for which we receive marketing approval;
•the revenue, if any, received from commercial sales of our product candidates
for which we receive marketing approval;
•the costs and timing of preparing, filing and prosecuting patent applications,
maintaining and enforcing our intellectual property rights and defending any
intellectual property-related claims;
•the effect of competing technological and market developments; and
•the extent to which we acquire or invest in businesses, products and
technologies, including entering into licensing or collaboration arrangements
for product candidates, although we currently have no commitments or agreements
to complete any such acquisitions or investments in businesses.
Identifying potential product candidates and conducting preclinical testing and
clinical trials is a time consuming, expensive and uncertain process that takes
years to complete, and we may never generate the necessary data or results
required to obtain marketing approval and achieve product sales. In addition,
our product candidates, if approved, may not achieve commercial success. Our
commercial revenues, if any, will be derived from sales of products that we do
not expect to be commercially available for many years, if ever. Accordingly, we
will need to obtain substantial additional funds to achieve our business
objectives.
Adequate additional funds may not be available to us on acceptable terms, or at
all. To the extent that we raise additional capital through the sale of equity
or convertible debt securities, the ownership interest of existing stockholders
will be diluted, and the terms of these securities may include liquidation or
other preferences that adversely affect the rights of common stockholders.
Additional debt financing and preferred equity financing, if available, may
involve agreements that include covenants limiting or restricting our ability to
take specific actions, such as incurring additional debt, making capital
expenditures or declaring dividends and may require the issuance of warrants,
which could potentially dilute the ownership interest of existing stockholders.
The terms of our 2019 Credit Facility with K2HV preclude us from paying
dividends on our equity securities without their consent. If we lack sufficient
capital to expand our operations or otherwise capitalize on our business
opportunities, our business, financial condition and results of operations would
be materially adversely affected.
If we raise additional funds through collaborations, strategic alliances or
licensing arrangements with third parties, we may have to relinquish valuable
rights to our technologies, future revenue streams, research programs, or
product candidates or grant licenses on terms that may not be favorable to us.
If we are unable to raise additional funds through equity or debt financings
when needed, we may be required to delay, limit or terminate our product
development programs or any future commercialization efforts or grant rights to
develop and market product candidates to third parties that we would otherwise
prefer to develop and market ourselves.
Contractual Obligations and Commitments
We are a smaller reporting company, as defined by Rule 12b-2 of the Exchange
Act, and are not required to provide this information.

Off-Balance Sheet Arrangements
As of December 31, 2020, we did not have, and we do not currently have, any
off-balance sheet arrangements, as defined in the rules and regulations of the
SEC.


                                       87
--------------------------------------------------------------------------------
  Table of Contents
Critical Accounting Policies and Use of Estimates
Our management's discussion and analysis of financial condition and results of
operations are based on our consolidated financial statements which are prepared
in accordance with generally accepted accounting principles, or GAAP, in the
United States of America. The preparation of our consolidated financial
statements and related disclosures requires us to make estimates and assumptions
that affect the reported amount of assets, liabilities, revenue, costs and
expenses, and related disclosures. We believe that the estimates and assumptions
involved in the accounting policies described below may have the greatest
potential impact on our consolidated financial statements and, therefore,
consider these to be our critical accounting policies. We evaluate our estimates
and assumptions on an ongoing basis using historical experience, known trends
and events and various other factors that are believed to be reasonable under
the circumstances, the results of which form the basis for making judgments
about the carrying values of assets and liabilities that are not readily
apparent from other sources. Our actual results may differ from these estimates
under different assumptions and conditions.
Accrued Research and Development Expenses
As part of the process of preparing our consolidated financial statements, we
are required to estimate our accrued research and development expenses. This
process involves reviewing open contracts and purchase orders, communicating
with our personnel to identify services that have been performed on our behalf
and estimating the level of service performed and the associated costs incurred
for the services when we have not yet been invoiced or otherwise notified of the
actual costs. The majority of our service providers invoice us in arrears for
services performed, on a pre-determined schedule or when contractual milestones
are met; however, some require advanced payments. We make estimates of our
accrued expenses as of each balance sheet date in our consolidated financial
statements based on facts and circumstances known to us at that time. Examples
of estimated accrued research and development expenses include fees paid to:
•CROs in connection with performing research services on our behalf including,
but not limited to, clinical trials and preclinical studies;
•investigative sites and other providers in connection with clinical trials and
preclinical studies;
•other research and development service providers such as academic institutions
and laboratory services providers in connection with discovery, preclinical and
clinical development activities; and
•vendors related to product manufacturing, development and distribution of
clinical supplies.
We base our expenses related to clinical trials and preclinical studies on our
estimates of the services received and efforts expended pursuant to quotes and
contracts with multiple CROs, investigative sites, laboratories and other
providers that conduct and manage those studies on our behalf. The financial
terms of these agreements are subject to negotiation, vary from contract to
contract and may result in uneven payment flows. There may be instances in which
payments made to our vendors will exceed the level of services provided and
result in a prepayment of the clinical expense. Payments under some of these
contracts depend on factors such as the successful enrollment of patients and
the completion of milestones. In accruing service fees, we estimate the time
period over which services will be performed, enrollment of patients, number of
sites activated and the level of effort to be expended in each period. If the
actual timing of the performance of services or the level of effort varies from
our estimate, we adjust the accrual or amount of prepaid expense accordingly.
Although we do not expect our estimates to be materially different from amounts
actually incurred, our understanding of the status and timing of services
performed relative to the actual status and timing of services performed may
vary and may result in us reporting amounts that are too high or too low in any
particular period. To date, we have not made any material adjustments to our
prior estimates of accrued research and development expenses.
Stock-Based Compensation
We measure stock options and other stock-based awards granted to employees and
directors based on the fair value on the date of grant and recognize the
corresponding compensation expense of those awards over the requisite service
period, which is generally the vesting period of the respective award.
Generally, we issue stock options and restricted stock awards with only
service-based vesting conditions and record the expense for these awards using
the straight-line method, adjusting for pre-vesting forfeitures in the period in
which the forfeitures occur. We measure stock-based awards granted to
consultants and non-employees based on the fair value of the award on the date
of the grant. Compensation expense is recognized over the period during which
services are rendered by such consultants and non-employees until completed.
Prior to January 1, 2020, we accounted for these awards in accordance with the
provisions of ASC Subtopic 505-50, Equity-Based Payments to Non-employees ("ASC
505-50"). Under ASC 505-50, share-based awards to nonemployees were subject to
periodic fair value re-measurement at the end of each financial reporting period
prior to completion of the service.


                                       88

————————————————– ——————————

  Table of Contents
As discussed in Note 2 (Significant Accounting Policies) to our consolidated
financial statements included elsewhere in this Annual Report on Form 10-K under
the heading "New Accounting Pronouncements - Adopted during the current period,"
we adopted ASU No. 2018-07, Stock-based Compensation: Improvements to
Nonemployee Share-based Payment Accounting (Topic 718), on January 1, 2020. As a
result, our accounting for nonemployee awards is now generally consistent with
that of employee awards. Beginning on January 1, 2020, the measurement date for
nonemployee awards is the date of grant without any subsequent changes in the
fair value of the award.

We estimate the fair value of each stock option grant using the Black-Scholes
option-pricing model. Use of this model requires that we make assumptions as to
the volatility of our common stock, the expected term of our stock options, the
risk-free interest rate for a period that approximates the expected term of our
stock options, and our expected dividend yield. Prior to May 2018, we were a
privately-held company with limited operating history and no company-specific
historical and implied volatility information and accordingly, we estimate our
expected volatility based on the historical volatility of a group of publicly
traded peer companies. We expect to continue to do so until such time as we have
adequate historical data regarding the volatility of our traded stock price. We
use the simplified method prescribed by SEC Staff Accounting Bulletin No. 107,
Share-Based Payment, to calculate the expected term of options granted to
employees and directors. We base the expected term of options granted to
consultants and non-employees on the contractual term of the options. We
determine the risk-free interest rate by reference to the U.S. Treasury yield
curve in effect at the time of grant of the award for time periods approximately
equal to the expected term of the award. Expected dividend yield is based on the
fact that we have never paid cash dividends and do not expect to pay any cash
dividends in the foreseeable future.

© Edgar Online, source Previews


Source link

]]>
Anti-abortion measure banning second trimester procedure will not appear in Michigan’s November ballot https://www.cliftonparkarena.com/anti-abortion-measure-banning-second-trimester-procedure-will-not-appear-in-michigans-november-ballot/ Thu, 11 Mar 2021 05:33:49 +0000 https://www.cliftonparkarena.com/anti-abortion-measure-banning-second-trimester-procedure-will-not-appear-in-michigans-november-ballot/

LANSING – A voting measure to ban doctors from performing the dilation and evacuation procedure, or D&E procedure, will not go through the November ballot.

In June, the Michigan Elections Office found that the citizens’ initiative did not have the required number of valid signatures to be on the November ballot. Right to Life of Michigan, the group behind Michigan’s Values ​​Life petition, announced Tuesday that it will not dispute the finding.

“Instead of focusing on legal challenges regarding the counting process, we will focus on the crucial 2020 election,” Barbara Listing, president of Right to Life of Michigan said in a statement.

The measure would have made it a crime for a doctor to perform D&E. In 2018, about 7% of abortions in Michigan involved dilation and evacuation, which is typically used for abortions after the 14th week of pregnancy. It involves a combination of suction and manual extraction of the fetus and is usually performed during the second trimester of pregnancy.

The group submitted 380,000 signatures, but the office said it was missing 7,276 valid signatures, based on a review of a sample of 500 signatures.

Michigan’s Planned Parenthood Chapter pointed to the large number of votes in 2018 as one reason Michigan Values ​​Life couldn’t get enough signatures. The increased voter turnout forced the group to collect more signatures than in previous years.

“Today is a victory for every doctor and patient in Michigan, and for every person who has been forced to undergo traumatic procedures because bad laws passed by politicians backed by Right to Life demanded it.” said Lori Carpentier, president of Planned Parenthood Advocates of Michigan. and CEO in a press release.

“No more. The days of the right to life that dictated medical care in Michigan are over, and we couldn’t be happier to be the ones saying it,” she said.

Listing acknowledged the increased signature requirement, calling it “the biggest hurdle”. But there were other factors as well. She pointed out a competing prolife petition that she said “confuse people” and retrain volunteers for the new petitions law which was recently enacted. In the end, the group missed the number of signatures they wanted to send.

“Our volunteers did a great job, but most of the mistakes were things beyond our control, especially people not knowing their voter registration status or forgetting that they had already signed the petition,” Listing said.

“Because we were about 20,000 signatures below our target of 400,000, we gave way to Planned Parenthood to go our separate ways.”

MORE FROM MLIVE:

Mask mandate debate echoes 1980s seatbelt battles

‘We are devastated,’ Bone Island Grille co-owner said of employee’s positive COVID-19 test, temporary shutdown

Severe storm investigation: winds up to 95 mph in northern Michigan storms


Source link

]]>
How to Get a Loan and Apply Online With BridgePayday https://www.cliftonparkarena.com/apply-online-for-a-loan-with-bridgepayday-it-is-easy/ Thu, 03 Sep 2020 09:12:27 +0000 https://www.cliftonparkarena.com/?p=742 If you are thinking about making a big purchase, starting a home or business, or even starting a new car or a boat you may want to consider getting financing from a bank. You can apply for a loan online, though most lenders require that you be a resident of their region.

There are several ways to get a loan and apply online with BridgePayday. Their website will guide you through the process so you don’t have to spend a lot of time on it. Once you have established a good credit history, they have a line of loans available for any purpose, small or large.

If you have had bad credit before, the lender will not be able to approve you for a loan based solely on your credit history. They will need to see some assets such as a home or other asset that you have a claim on. For example, if you took out a personal loan several years ago when you had no collateral, the bank would not be able to approve you for a loan without a home equity loan (HEL).

Apply online for a loan with BridgePayday: it is easy

With a little over an hour of your time, you can go through the process and be approved for high quality short term loans.

After getting approved for the loan, you may decide to consolidate your debt and save money. Some people even use the money they saved to pay off their existing loan, or to buy a new car. Your lender can help you work out a payment plan and help you set up automatic payments for your new loan.

When you apply online, there is a personal or professional information form you must fill out. This is an essential step in the loan process, as it lets the lender know that you are serious about buying a home or paying off a vehicle, or even getting approved for a HEL. After filling out the form, the next step is to enter your contact information, such as your name, address, phone number, etc.

At this point, you will also need to determine whether you want to receive a cash loan from the lender, or you will need to use your credit card. In either case, you will fill out the same personal information forms, but after submitting the forms, you will receive an automated email orletter from the lender letting you know whether or not you have been approved for a loan.

Once your applications have been submitted, you will be given personal information about yourself, such as your social security number and the reason for your request. If you submit the forms accurately, your application will then be processed and you will be sent confirmation of approval or denial.

If you provide the lender with accurate and up to date information on your finances, you will be approved almost immediately. The lenders will check your income and repayment ability and will accept your credit report to help them assess whether or not you are financially responsible enough to handle a loan.

BridgePayday options for borrowers

BridgePayday has many options available to borrowers who cannot afford to pay their loans on their own. You can choose to get a one-time payment plan, which allows you to make one single payment on your new loan, or you can apply for a regular monthly payment plan that pays your debt.

The interest rate varies depending on the product you select and on the amount of money you are borrowing. There are repayment options available if you need to make extra payments, and many products have multiple payment options.

One question I get asked all the time is how to get a loan and apply online with BridgePayday. They have answers to that question, including answers about their rates, loan plans, and your options.

]]>
Online credit: discover a few tips before subscribing! https://www.cliftonparkarena.com/online-credit-discover-a-few-tips-before-subscribing/ Tue, 25 Aug 2020 14:24:45 +0000 http://www.cliftonparkarena.com/online-credit-discover-a-few-tips-before-subscribing/ With your loved ones, you share beautiful moments and beautiful projects to come. With Cream Bank , you can count on our remote support! Now, many steps can be taken online: pay your bills, apply for a credit card, complete your tax return, apply for a residency certificate and take out a car loan, home improvement loan or personal loan.

Why is it interesting to make your credit online?

online loan

In most financial institutions, to apply for a loan, you generally need to make an appointment, organize your agenda, travel, sign numerous documents, etc. All these steps can sometimes delay the implementation of your project.

Doing your procedures online and via your smartphone can, therefore, be very practical! You do it where and when you want, just like you already do for many other services.

And most of the time, if you need personalized contact, it’s still possible. Financial organizations have a team of experts who answer all your questions and advise you. They are generally available by phone, chat, or video call … So you combine the advantages of remote operations with those of human contact.

How to make sure you make your credit online safely?

How to make sure you make your credit online safely?

Doing everything on the web can be very convenient, but you still have to be sure to do it safely.

First precaution: check that you are on a secure site. The website link will then start with “https” and, sometimes, a small padlock is also displayed, especially when you transmit personal data.

Then, to confirm your credit request online, you will generally have to authenticate yourself using secure tools or enter security codes received by SMS, for example. You understood it, to carry out an online credit, security will also have to be in order!

Why do it at Cream Bank ?

Cream Bank aims to simplify the sector while responding to consumer behavior patterns and safety requirements.

Thus, Cream Bank has designed 100% online short term loans, which are managed entirely from a smartphone or tablet and in an ultra secure manner. You apply for a car loan, renovation, mobility, personal… and you make your project a reality.

The advantages of applying for your credit online at Cream Bank :

  • You do not need to open a bank account: you stay in your bank.
  • You don’t have to travel: you do your work where and when you want.
  • You don’t need a printer or sign lots of documents: you fill out an online form, download your supporting documents and sign your contract by electronic signature.
  • You receive an immediate response in principle, as soon as your request is accepted. The time to receive money on your account can be reduced to 1 day!
  • Do you need a personalized contact and advice for your request? A large team of experts is also at your disposal.
]]>
Government Agency online loan application guide for Employees and Pensioners https://www.cliftonparkarena.com/government-agency-online-loan-application-guide-for-employees-and-pensioners/ Fri, 31 Jul 2020 14:19:23 +0000 http://www.cliftonparkarena.com/government-agency-online-loan-application-guide-for-employees-and-pensioners/ How to submit an Government Agency loan application online

How to submit an Government Agency loan application online

Public employees and pensioners who are looking for a loan can resort to Social Institute ex ex Government Agency loans. Short term loans that give access to even large sums with which to face expenses of various kinds. But how to apply for funding? The online Government Agency loan request must be sent electronically.

However, the procedure for submitting the application varies according to whether the applicant is a public employee or pensioner. Employees must send the request through the Administration they belong to. It is therefore necessary to contact the public office where you are hired, in order to send the application for funding.

The transmission takes place electronically by the Administration, which acts as an intermediary between the civil servant and Social Institute.

However, the procedure for pensioners is different. In this case, in fact, we have several channels for the transmission of the application. Public pensioners who wish to apply for an Government Agency loan can choose to send the application independently, or by availing themselves of Social Institute assistance or authorized patronage.

Those who choose to transmit the application independently must connect to the Social Institute website and reach the service called Public Employee Management: services for Workers and Pensioners. Log in with Pin Social Institute is required for transmission of the application.

Download the Government Agency loan forms

Application forms can be downloaded directly from the official Social Institute website. To reach the models to be used for the Government Agency online loan request, you must first access the All modules section of the Social Institute website, and then choose the Public Employee Management filter from the right side menu.

At this point, simply use the additional filters to easily find the form of our interest. Specifically, the path to follow to find the demand models for Government Agency loans is: Public Employee Management; Member / Pensioner; Credit and social benefits. The Government Agency online loan application forms are available both in Pdf and zip format.

]]>
Loan for anything https://www.cliftonparkarena.com/loan-for-anything/ Sat, 02 May 2020 08:41:21 +0000 http://www.cliftonparkarena.com/loan-for-anything/ Loans are purchased to pay for a variety of reasons, but where you borrow them, it usually doesn’t matter. It is the same with other lenders – you can borrow here whatever you need – the loan is non-purpose.

Loan quickly and easily

Loan quickly and easily

The advantages of this loan include simply settling your debts and arrears, or fulfilling dreams that you can’t save enough money for.

The loan is handled without the need for various documentation. Paperwork is simply easy and minimal. You can count on a fair deal. The loan details will be communicated in advance and you will not be surprised by any hidden fees later. A professional consultant will be happy to discuss anything unclear with you. You can also use the loan to settle execution and pledges.

Quickly arranged loans

Quickly arranged loans

The easiest way to apply for a loan is to fill in the application form online. You can get information about pre-approving the loan in minutes. Loans are obtained without examining the debtor registers. Loans can range from 100,000 to 5,000,000 dollars. There is no need to provide information about your income. Persons who have property in their personal possession may apply for a loan. The guarantee is secured by a real estate pledge and no guarantor is required. You can use the houses, flats, offices, land, cottages, business premises etc.

Repayment of the loan

Lender provides short term loans with a maturity of up to 20 years maximum. Repayments must be made on a monthly monthly basis from your bank account. To do this, it is necessary to have a standing order for payment of installments. There is no limit to making extraordinary installments – they can be made at any time, or the loan can be repaid completely early. If you make extraordinary repayments on the loan, the agreed monthly repayments may eventually be reduced. Loan money will be obtained immediately after all the requirements have been settled.

You don’t pledge collateral, nor do you agree to use the money for a specific purpose. Personal loans include credit cards and signature loans from your bank or credit union. Loans from online lenders and peer-to-peer lenders often are personal loans as well.

]]>
How to Get a Loan from Banks and Online Lenders? https://www.cliftonparkarena.com/how-to-get-a-loan-from-banks-and-online-lenders/ Tue, 07 Apr 2020 03:53:36 +0000 http://www.cliftonparkarena.com/how-to-get-a-loan-from-banks-and-online-lenders/ Understand the process from start to finish

Lending money can help you get things done, but the process can be complicated. Mistakes can be costly and can lead to a loan request being rejected. If you need credit, learn what to expect and what you can do in advance.

What kind of loan?

What kind of loan?

The first step is to figure out what you need. The type of loan you receive will depend on what you plan to do with the money. Some common types of loans include:

  • Car loans to buy vehicles
  • Home loans (mortgage loans), including other mortgages to buy a home or borrow from equity in your home
  • Personal loans, which can be used for almost any purpose
  • Business loans to start or expand your business
  • Educational loans (student loans)
  • short term loans

In some cases you may not have many choices – it is unlikely that someone will give you enough to buy a home unless you use a loan designed for the purpose. Using a loan that suits your need will improve your chances of getting approved and reduce your costs.

Apply for a loan

Apply for a loan

You are ready to get a loan once you have:

  • The best type of loan is selected
  • He bought the competition
  • You made a loan, and
  • Run the numbers

At this point, you can go to your lender and apply. The process is easy to start: simply tell the lender you want to lend money to and tell them what you will do with the funds (if necessary). They will explain the next steps and how long the process will take.

When you complete the application, you will provide information about yourself and your finances. For example, you will need to bring an ID, provide an address and social security number (or equivalent), and provide information about your income.

Go through the risk

Go through the risk

After applying, the loan will evaluate you as a potential loan. This process may be instantaneous or may take several weeks. For example, home loans last longer than credit card offers because more is at stake. Mortgage loans require extensive documentation, such as bank statements and payables to pay off proof that you have the ability to repay. You can facilitate the process by yourself by getting everything in order for a few months before applying.

During redemption, lenders will withdraw their loan (or just use a credit score) and review your application. They may call you occasionally and ask you to clarify or prove something – that’s usually a good sign. When lenders ask for details, it means that they take into account the seriousness and are more likely to offer competitive rates.

]]>
How to protect yourself when you get a hard money loan? https://www.cliftonparkarena.com/how-to-protect-yourself-when-you-get-a-hard-money-loan/ Sun, 22 Mar 2020 04:14:13 +0000 http://www.cliftonparkarena.com/how-to-protect-yourself-when-you-get-a-hard-money-loan/ To understand where hard money loans come from, we can go back to the horse and buggy days. The most commonly used form of money among early American settlers was gold coins.

Native Americans, on the other hand, sold goods such as beads and diapers. If you borrowed money, you were expected to pay it back, and collateral was not always part of the contract. Hard money loans are not usually secured.

In the negative, if you did not return it, you could be affected.

cash

In an effort to settle the colonies, the United States government donated land in exchange for the department’s promise to live on land, grow things such as corn or cotton, and raise livestock.

To provide shelter, settlers cut down several trees and made their own log cabins. Today, we expect to either buy an existing home or pay a builder to build a new home for us, and we rarely have a free and clear home. Hard money loans versus cash loan purchases

Buying money is money that a home buyer borrows to buy a home. This home can be almost any type of structure, from a single-family residence, multiple units, condominiums, townhomes or a cooperative to a modular or manufactured home.

Buying money forms part of the purchase price. The loan is secured by the property, that is, if the buyer ceases to make interest, the lender may have the right to seize the home and sell that home to recover his money.

The bad money that is secured for real estate is a loan other than buying money.

The money is lent to a lender, which is not always used to buy a home. You can get a hard money loan with no homeownership at all – without any security for that loan – by ensuring the lender that you are a good credit risk. A cash advance credit card is a hard money loan.

Or you could get a hard money loan that was provided for home equity but was not part of the original purchase price. Your money’s insurers usually want the borrower and the security to qualify for a hard money loan.

Types of hard money loans

money

Most guaranteed lenders prefer collateral with securitization for lending. That collateral, such as a house, is returned to the hard money lender if the debt is borrowed and the house eventually goes to foreclosure. Real estate is a great means of securing a hard cash loan if the property in question has equity. One of the reasons for getting rid of a mortgage in 2007 was the value of a house that fell, which is why many lenders hold the sack without any security.

Some buyers use hard money loans as a routine to buy investment properties that need to be fixed. They will save their cash and pay high positions to take out a hard money loan with a short repayment term. The problem with this approach is that some buyers write their offers of purchase as all cash and show money bills as proof of funds.

However, if they get a loan, the transaction is NOT all cash.

Here are the common types of hard cash loans:

Here are the common types of hard cash loans:

  • Mortgage refinancing is a hard money loanRefinancing disburses one or more loans secured for a property, resulting in a new loan, generally with a larger principal balance. The homeowner can refinance without receiving any income by either transferring the cost of the new loan into equity or paying the loan costs out of the borrower’s pocket.In refinancing cash, the customer takes on a new loan that is greater than the amount of the old loans plus the cost of obtaining the money. Money above these two things is called “cash for the borrower.” This is net refinancing income. Many cash refinances are subject to deficiency judgments.
  • Capital loan loans are hard money loansHome equity finance short term loans fairly quickly and subordinated to an existing first mortgage. In other words, a home equity loan falls into second or third position. Borrowers cannot obtain a home equity loan in all 50 states.
  • Bridge loans are hard money loansBridge loans are used by sellers who want to buy a new home before selling an existing home but need cash from an existing home. You will see bridges used more often in vendor markets than in shopping markets.
]]>